Wegovy belongs to a group of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. It contains the active ingredient semaglutide, which mimics the activity of our brain’s natural GLP-1.

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

“Another mechanism that could be very important for this current study is that GLP-1 receptor agonists can actually decrease clumping of blood platelets, and that, in itself, could decrease the ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 agonists and AUD medications. The study followed 227,886 individuals with AUD ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonists (GIP-RA) causes almost as much weight loss as ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

"Another mechanism that could be very important for this current study is that GLP-1 receptor agonists can actually decrease clumping of blood platelets, and that, in itself, could decrease the ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

The company reported its dual GLP-1/GIP co-agonist drug VK2735 saw up to an average of 8.2% weight loss over 28 days on its highest-tested dose of 100 mg. Sources: AstraZeneca , ObesityWeek ...

“Our progress in the third quarter was highlighted by the compelling topline results from our Phase 1 study of TERN-601, which demonstrated class-leading potential as a differentiated, once-daily, ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...